key: cord-0754451-5vfuo8kd authors: Ngo Nsoga, M.-T.; Kronig, I.; Perez Rodriguez, F. J.; Sattonnet-Roche, P.; Da Silva, D.; Helbling, J.; Sacks, J. A.; de Vos, M.; Boehm, E.; Gayet- Ageron, A.; Berger, A.; Jacquerioz-Bausch, F.; Chappuis, F.; Kaiser, L.; Schibler, M.; Renzoni, A.; Eckerle, I. title: Diagnostic accuracy of PanbioTM rapid antigen tests on oropharyngeal swabs for detection of SARS-CoV-2 date: 2021-02-01 journal: nan DOI: 10.1101/2021.01.30.21250314 sha: cc7229256726cfa60827f2865a66a7860da030d2 doc_id: 754451 cord_uid: 5vfuo8kd Background Antigen-detecting rapid diagnostic tests (Ag-RDTs) for the detection of SARS-CoV-2 offer new opportunities for testing in the context of the COVID-19 pandemic. Nasopharyngeal swabs (NPS) are the reference sample type, but oropharyngeal swabs (OPS) may be a more acceptable sample type in some patients. Methods We conducted a prospective study in a single screening center to assess the diagnostic performance of the PanbioTM COVID-19 Ag Rapid Test (Abbott) on OPS compared with reverse-transcription quantitative PCR (RT-qPCR) using NPS. Results 402 outpatients were enrolled in a COVID-19 screening center, of whom 168 (41.8%) had a positive RT-qPCR test. The oropharyngeal Ag-RDT sensitivity compared to nasopharyngeal RT-qPCR was 81% (95%CI: 74.2-86.6). Two false positives were noted out of the 234 RT-qPCR negative individuals, which resulted in a specificity of 99.1% (95%CI: 96.9-99.9) for the RDT. For cycle threshold values [≤] 26.7 ([≥] 1E6 SARS-CoV-2 genomes copies/mL, a presumed cut-off for infectious virus), 96.3% sensitivity (95%CI: 90.7-99.0%) was obtained with the Ag-RDT using OPS. Interpretation Based on our findings, the diagnostic performance of the PanbioTM Covid-19 RDT with OPS samples meet the criteria required by the WHO for Ag-RDTs (sensitivity [≥] 80% and specificity [≥] 97%). Antigen-detecting rapid diagnostic tests (Ag-RDTs) for the detection of SARS-CoV-2 offer new opportunities for testing in the context of the COVID-19 pandemic. Nasopharyngeal swabs (NPS) are the reference sample type, but oropharyngeal swabs (OPS) may be a more acceptable sample type in some patients. We conducted a prospective study in a single screening center to assess the diagnostic performance of the Panbio TM COVID-19 Ag Rapid Test (Abbott) on OPS compared with reverse-transcription quantitative PCR (RT-qPCR) using NPS. Based on our findings, the diagnostic performance of the Panbio TM Covid-19 RDT with OPS samples meet the criteria required by the WHO for Ag-RDTs (sensitivity ≥ 80% and specificity ≥ 97%). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The SARS-CoV-2 pandemic has killed millions of people worldwide (1) . Large scale testing allows for identification and isolation of infected individuals, and quarantining contacts, thus limiting community transmission. Currently, SARS-CoV-2 RT-qPCR performed on nasopharyngeal swabs (NPS) is the gold-standard diagnostic test. While displaying excellent sensitivity and specificity, RT-qPCR is costly, subject to reagent and material shortages during pandemics, and requires experienced personnel and complex infrastructure. Antigen rapid diagnostic tests (Ag-RDTs) are easy to use, more affordable, decentralizable, and provide quick results; offering an attractive alternative to RT-qPCR during pandemics. Their drawbacks are mainly reduced sensitivity relative to RT-qPCR. The World Health Organization (WHO) considers a sensitivity ≥ 80% and a specificity ≥ 97% as acceptable performance for SARS-CoV-2 Ag-RDTs (2) . Currently, only validations of Ag-RDTs performed with NPS have shown satisfactory results (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) , and no studies have evaluated Ag-RDTs using oropharyngeal swabs (OPS). OPS sampling could be a useful alternative to NPS sampling, as seen with RT-qPCR tests (13, 14) . Here we describe a prospective study comparing the diagnostic performances of an Ag-RDT using OPS with RT-qPCR using NPS for detection of SARS-CoV-2. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.30.21250314 doi: medRxiv preprint The study was approved by the cantonal ethics committee (Commission Cantonale d'Ethique de la Recherche, CCER, Geneva, Nr. 2020-02323). All enrolled patients provided written informed consent form. The study took place from November 3 to 19, 2020, at an outpatient SARS-CoV-2 screening site at the Geneva University Hospitals. The majority of patients had symptoms compatible with SARS-CoV-2 infection, and a small proportion were asymptomatic contacts. All participants were ≥ 16 years old. Participants were swabbed twice: one NPS performed by a nurse at the screening site, for the reference RT-qPCR; and an OPS done by an experienced doctor, using a tongue depressor in a well-lit environment with an emphasis on consistent technique, for the Ag-RDT. A pilot study tested 28 RT-qPCR-positive individuals without ensuring the back of the oropharynx was reached, yielding only 11 Ag-RDT positives (Supplemental table 1 ). Therefore, patients were only included if the posterior wall of the oropharynx could be reached. The clinical data collected for each patient was: duration of any symptoms when samples were collected, potential close contact with a positive person within 14 days, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.30.21250314 doi: medRxiv preprint symptoms (rhinorrhea, odynophagia, myalgia, chills, dry vs productive cough, hemoptysis, fever, anosmia, ageusia, gastrointestinal symptoms, asthenia, dyspnea, chest pain and headache), and comorbidities (hypertension, cardiovascular disease, chronic lung disease, diabetes, chronic renal failure, active cancer, severe immunosuppression, pregnancy and obesity (BMI> 40 kg/m2)). Aside from the sample type, the Panbio TM (Abbott) Ag-RDT device was run and read by a biologist according to the manufacturer's protocol. Equivocal results were read by a second healthcare worker. All NPS samples were analyzed using the Cobas ® SARS-CoV-2 RT-PCR assay on the 6800 system (Roche), targeting ORF1 and the E-gene. Cycle-threshold (Ct) values for the E-gene were converted into viral load (VL) with the following formula: log 10 SARS-CoV-2 copies/mL=(Ct-44.5)/-3.3372. Ag-RDT sensitivity and specificity was determined relative to RT-PCR. With a positivity rate of 37.5%, and an Ag-RDT sensitivity/specificity of 85%/95%, a sample size of 400 could determine sensitivity and specificity with confidence intervals (CI) of 79.3-90.7% and 92.3-97.7%, respectively. Fischer's exact test was used to compare Ag-RDT sensitivity by Ct values (above/below 26.7). All analyses were performed . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.30.21250314 doi: medRxiv preprint using STATA version intercooled 16 (Stata Corp., College Station, TX, USA). Statistical significance was defined as p<0.05 (two-sided). During the study period, 402 participants were included. Eight patients were excluded either because the throat was insufficiently accessible or because consent . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 1, 2021. (3, (6) (7) (8) (9) . Similarly, samples from <5 DPOS yielded a sensitivity between 77.2 and 94.8% (3, 5, 6, 8, 9) . For some patients in whom NPS sampling is not feasible, OPS could be an attractive alternative, thus OPS sample validation is critical. This is the first publication investigating the diagnostic accuracy of the Panbio TM Ag-RDT using OPS. Our results meet show this off-label use to still meets the WHO targets of ≥ 80% sensitivity and ≥ 97% specificity (2) . Interestingly, while ensuring high OPS sample quality, we obtained similar results to our previously published NPS evaluation, with no statistical difference in sensitivity and specificity (3) . We previously demonstrated similar clinical and analytical sensitivities between NPS and OPS sampling for SARS-CoV-2 detection using RT-qPCR (14) . However, some studies showed reduced(13) sensitivity and lower rates of virus isolation in cell . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.30.21250314 doi: medRxiv preprint culture for OPS when compared to NPS, suggesting a risk of reduced Ag-RDT sensitivity when using OPS(15). Our present study shows that despite the use of OPS, contrary to manufacturer recommendations, we obtained highly reliable results. Similar to studies on NPS specimens, the highest sensitivity was seen in the early symptomatic period as well as for patients presenting with high nasopharyngeal VL. Although a few positive samples with lower Ct values were missed, the majority of false-negative samples were from individuals with high Ct values (≥30), corresponding to a low VL below the presumed cut-off for infectious virus (Ct≤26.7 in our hands); these results suggest that these individuals are not likely to be contagious and that these false-negative Ag-RDT results should not result in further transmission. In conclusion, the use of Ag-RDTs with OPS might prove to be an acceptable alternative to NPS, and could increase test acceptance for selected groups such as children. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 1, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.30.21250314 doi: medRxiv preprint 1 4 CoV-2 RNA copy numbers/mL. Note: Two samples were excluded because of low viral load (positive signal in ORF1 assay but negative signal in E-gene target, thus excluded from the graph. Both samples gave a negative RDT result). B. Ct values, viral load, days post symptom onset and Ag-RDT results for 139 patients for which information on day of symptom onset was available. Dotted line: Ct value of 26.7 or 1E6 SARS-CoV-2 RNA copy numbers/mL. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 1, 2021. COVID-19) Dashboard COVID-19 Diagnostic accuracy of two commercial SARS-CoV-2 Antigendetecting rapid tests at the point of care in community-based testing centers. medRxiv Evaluation of the Panbio Covid-19 rapid antigen detection test device for the screening of patients with Covid-19 Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms Antigen rapid tests, nasopharyngeal PCR and saliva PCR to detect SARS-CoV-2: a prospective comparative clinical trial. medRxiv Real-life validation of the Panbio COVID-19 Antigen Rapid Test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection. medRxiv Multicenter evaluation of the Panbio TM COVID-19 Rapid Antigen-Detection Test for the diagnosis of SARS-CoV-2 infection. medRxiv Evaluation of the Panbio TM rapid antigen test for SARS-CoV-2 in primary health care centers and test sites. medRxiv Analytical and Clinical Performance of the Panbio COVID-19 Antigen-Detecting Rapid Diagnostic Test. medRxiv Nasopharyngeal Swabs Are More Sensitive Than Oropharyngeal Swabs for COVID-19 Diagnosis and Monitoring the SARS-CoV-2 Load Sensitivity of nasopharyngeal, oropharyngeal, and nasal wash specimens for SARS-CoV-2 detection in the setting of sampling device shortage Specificity 100% (95% CI = 87 We thank all nurses and staff at the testing Centre Sectors of our institution as well as the patients for their willingness to participate in the study.. CC-BY-NC-ND 4.0 International license It is made available under a